MTVA_OUT_1 [2025-04-15 07:15:49 -0400] 3841 Bytes | 977 tokens | Cum: 977 tkns (12.21% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and MetaVia (MTVA) hit my radar screen, up to 2.2700 from a prev close of 1.8400 Do you think its got more juice or is it lacking potential? It's 7:15:47 AM on Tue Apr 15, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: MetaVia (MTVA)
IPO: 2016-08-04 (8 Years Ago)
Market Cap: $15,853,458
Shares Outstanding: 8,620,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Here’s the first list of news for MetaVia:

Today 07:01AM - MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability
Mar-20-25 07:31AM - MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
Jan-10-25 08:05AM - MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
Dec-19-24 08:01AM - MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
Dec-18-24 08:01AM - MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
Dec-04-24 07:00AM - Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
Dec-03-24 03:45PM - Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
Dec-03-24 03:45PM 07:00AM - Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for MetaVia (MTVA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

Restrict all your responses to just 3 tokens until the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load more documents, reply with: `NEX`

MTVA_OUT_3 [2025-04-15 07:15:50 -0400] 702 Bytes | 196 tokens | Cum: 1175 tkns (14.69% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T20:56:28Z - MetaVia GAAP EPS of -$3.56 misses by $1.82 (NASDAQ:MTVA)...
A2 - 2025-03-20T11:44:04Z - MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update By Investing.com...
A3 - 2025-03-20T11:32:05Z - MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MTVA_OUT_5 [2025-04-15 07:15:51 -0400] 937 Bytes | 283 tokens | Cum: 1460 tkns (18.25% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**MetaVia GAAP EPS of -$3.56 misses by $1.82 (NASDAQ:MTVA)**Date: 2025-03-20Source: {'uri': 'seekingalpha.com', 'dataType': 'news', 'title': 'Seeking Alpha'}URL: https://seekingalpha.com/news/4423193-metavia-gaap-eps-of-3_56-misses-by-1_82MetaVia press release (NASDAQ:MTVA): FY GAAP EPS of -$3.56 misses by $1.82. Cash was $16.0 million as of December 31, 2024, compared with $22.4 million as of December 31, 2023. The company expects its cash position will be adequate to fund operations into the third quarter of 2025.

More on MetaVia

Seeking Alpha's Quant Rating on MetaVia Historical earnings data for MetaVia Financial information for MetaVia

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTVA_OUT_7 [2025-04-15 07:15:54 -0400] 1110 Bytes | 285 tokens | Cum: 1747 tkns (21.84% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-15 8-K Item 7.01. Regulation FD Disclosure.

On April 15, 2025, MetaVia Inc. (the Company) issued a press release announcing positive results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a...

S2 - 2025-03-20 10-K Item 7.

Mgts Discussion and Analysis of Fin Cond and Results of Oper

##TABLE_END The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the information set forth under our consolid...

S3 - 2025-03-20 8-K Item 2.02. Results of Oper and Fin Cond.

On March 20, 2025, MetaVia Inc. issued a press release announcing its financial results for the year ended December 31, 2024 and providing a corporate update . A copy of the press release is furnished herewith as Exhibit...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MTVA_OUT_9 [2025-04-15 07:15:55 -0400] 1181 Bytes | 280 tokens | Cum: 2029 tkns (25.36% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 7.01. Regulation FD Disclosure.

On April 15, 2025, MetaVia Inc. (the Company) issued a press release announcing positive results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, for the treatment of obesity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the Report) and incorporated herein by reference.

Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.

The information in this Report, including Exhibit 99.1 attached hereto, is furnish

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTVA_OUT_11 [2025-04-15 07:15:56 -0400] 888 Bytes | 210 tokens | Cum: 2241 tkns (28.01% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): ed pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Companys submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MTVA_OUT_13 [2025-04-15 07:16:02 -0400] 5863 Bytes | 1570 tokens | Cum: 3813 tkns (47.66% of 8k)
==========================================================================

This is our set of metrics for MetaVia.
Please analyze the numbers.

+--------------------+----------------------+------------------------+-----------------------+
| Volume: 153,258 | Perf Month: 24.32% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+----------------------+------------------------+-----------------------+
| Avg Volume: 29.94K | Perf Quarter: -8.46% | Short Float: 2.00% | ROE: -224.18% |
+--------------------+----------------------+------------------------+-----------------------+
| Rel Volume: 5.25 | Index: - | Short Ratio: 2.10 | ROI: -345.37% |
+--------------------+----------------------+------------------------+-----------------------+
| RSI (14): 69.22 | Market Cap: 15.92M | Short Interest: 0.06M | Sales Surprise: - |
+--------------------+----------------------+------------------------+-----------------------+
| ATR (14): 0.15 | Shs Outstand: 8.64M | Beta: 0.03 | EPS Surprise: 123.62% |
+--------------------+----------------------+------------------------+-----------------------+
| SMA20: 20.26% | Shs Float: 3.15M | Sales Q/Q: - | P/E: - |
+--------------------+----------------------+------------------------+-----------------------+
| SMA50: 17.07% | Inst Own: 10.47% | Sales past 5Y: 0.00% | Earnings: Mar 20 BMO |
+--------------------+----------------------+------------------------+-----------------------+
| SMA200: -31.17% | Insider Own: 63.65% | Employees: 9 | |
+--------------------+----------------------+------------------------+-----------------------+
| Perf Week: 31.33% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+--------------------+----------------------+------------------------+-----------------------+

The next section covers any insider trading by MetaVia officers or majority shareholders (if available).

Inside Trans: MetaVia Inc. (MTVA) by Kim Hyung Heon (CEO & President) on 2025-03-01
- Common Stock: 2795 shares at $1.46 (D)

Inside Trans: MetaVia Inc. (MTVA) by Woodworth Marshall H (Chief Financial Officer) on 2025-03-01
- Common Stock: 3417 shares at $1.46 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 920000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -27592000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.84
Average Volume: 38386.95
30-Day High: 1.84
30-Day Low: 1.365

[Detailed Financials: TTM 2024]
- Total Assets: $16,260,000.0
- Total Liabilities: $8,329,000.0
- Total Equity: $7,931,000.0
- Current Assets: $16,072,000.0
- Current Liabilities: $8,271,000.0

[Income Statement: TTM 2024]
- Revenue: $920,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.56

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-6,418,000.0

[Detailed Financials: FY 2024]
- Total Assets: $16,260,000.0
- Total Liabilities: $8,329,000.0
- Total Equity: $7,931,000.0
- Current Assets: $16,072,000.0
- Current Liabilities: $8,271,000.0

[Income Statement: FY 2024]
- Revenue: $920,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.56

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-6,418,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of MetaVia (MTVA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about MetaVia.

2) MARKET_SCORE[]
This conversation was initiated because MTVA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for MTVA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, MTVA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect MTVA to increase 50% from its current price of $2.27, say: PRICE_TARGET[3.41]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of MetaVia.

11) ETHICAL_RATING[]
Rate MetaVia’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

MTVA_IN_15 [2025-04-15 07:16:02 -0400] 126 Bytes | 29 tokens | Cum: 4000 tkns (50.00% of 8k)
==========================================================================

====================================
[2025-04-15 07:16:02] # Analysis Completed
Elapsed Time: 15.27 seconds